The stock price of Agios Pharmaceuticals Inc (NASDAQ: AGIO) has plunged by -4.09 when compared to previous closing price of 46.40, but the company has seen a -8.25% decline in its stock price over the last five trading sessions. benzinga.com reported 2024-08-01 that On Thursday, Agios Pharmaceuticals Inc AGIO released topline results from the global Phase 3 ACTIVATE-KidsT study of mitapivat in children aged 1 to
Is It Worth Investing in Agios Pharmaceuticals Inc (NASDAQ: AGIO) Right Now?
AGIO has 36-month beta value of 0.78. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AGIO is 55.38M, and currently, short sellers hold a 5.76% ratio of that float. The average trading volume of AGIO on August 02, 2024 was 770.39K shares.
AGIO’s Market Performance
The stock of Agios Pharmaceuticals Inc (AGIO) has seen a -8.25% decrease in the past week, with a 5.83% rise in the past month, and a 32.20% gain in the past quarter. The volatility ratio for the week is 4.83%, and the volatility levels for the past 30 days are at 4.24% for AGIO. The simple moving average for the last 20 days is -3.43% for AGIO stock, with a simple moving average of 45.64% for the last 200 days.
Analysts’ Opinion of AGIO
Piper Sandler, on the other hand, stated in their research note that they expect to see AGIO reach a price target of $41. The rating they have provided for AGIO stocks is “Overweight” according to the report published on February 03rd, 2023.
Goldman gave a rating of “Neutral” to AGIO, setting the target price at $32 in the report published on November 17th of the previous year.
AGIO Trading at 1.87% from the 50-Day Moving Average
After a stumble in the market that brought AGIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.62% of loss for the given period.
Volatility was left at 4.24%, however, over the last 30 days, the volatility rate increased by 4.83%, as shares surge +5.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +34.08% upper at present.
During the last 5 trading sessions, AGIO fell by -8.25%, which changed the moving average for the period of 200-days by +92.47% in comparison to the 20-day moving average, which settled at $46.20. In addition, Agios Pharmaceuticals Inc saw 99.82% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AGIO starting from Gheuens Sarah, who sale 3,705 shares at the price of $43.85 back on Jul 01 ’24. After this action, Gheuens Sarah now owns 43,736 shares of Agios Pharmaceuticals Inc, valued at $162,464 using the latest closing price.
Goff Brian, the Chief Executive Officer of Agios Pharmaceuticals Inc, sale 12,115 shares at $48.84 during a trade that took place back on Jun 05 ’24, which means that Goff Brian is holding 67,192 shares at $591,697 based on the most recent closing price.
Stock Fundamentals for AGIO
Current profitability levels for the company are sitting at:
- -13.36 for the present operating margin
- 0.81 for the gross margin
The net margin for Agios Pharmaceuticals Inc stands at -11.99. The total capital return value is set at -0.49. Equity return is now at value -39.61, with -35.24 for asset returns.
Based on Agios Pharmaceuticals Inc (AGIO), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -4.4.
Currently, EBITDA for the company is -384.86 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of 84.21. The receivables turnover for the company is 8.52for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.84.
Conclusion
To put it simply, Agios Pharmaceuticals Inc (AGIO) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
